




INVEST LIKE A PRO, WITH THE PROS!



Good morning!



The New Green Frontier Cannabis Investor Conference was a great success.

[Watch the replay here.](#)

My opening remarks start at 35:05, and the panel I moderated, Growing Technologies and Innovation, begins at 59:30.

Gene Simmons, who was a hoot, can be seen at 4:02:25.



Ryan Irvine weeks starts now.

Today's Digest cover story is an idea from the KeyStocks.com founder, that is one of the **best performing stocks on the TSX this year.**

Plus he'll have some general commentary on growth stocks amid this jittery earnings season.

Tomorrow is our live stream with Ryan at 2 pm ET.

He'll have **five Top Picks** for you.

[Watch the stream here.](#)

Morning Need to Know

Getting you ready for your investing day

November 20, 2018

**Written & compiled by Mark Bunting, Publisher,
Capital Ideas Media**



CANADIAN ANALYSTS' CALLS

INITIATIONS

TFI Int'l (TSX:TFII) Industrial Alliance Securities starts coverage with a "strong buy" and price target of \$60 (Canadian).

Brookfield Business Partners (TSX:BBU.UN;NYSE:BBU) BMO Nesbitt Burns starts coverage with an "outperform".

Bellus Health (TSX:BLUE) Mackie Research raises the price target to \$2.20 from \$1 and maintains "speculative buy" after the company announced positive Phase 1 data for its treatment for chronic cough. **The stock is up 132% since Mackie re-launched coverage.** BLU closed Monday at \$0.95.

Precision Drilling (TSX:PD) Citigroup upgrades

to "buy" and moves the target to \$5 from \$3.50 saying the "*price is finally right for investors to jump into PD shares.*"

IPL Plastics (TSX:IPLP) BMO Nesbitt Burns upgrades to "outperform" and maintains a \$13 target saying it would be "*an aggressive buyer at current levels*".



U.S. ANALYSTS' CALLS

INITIATIONS

ADT (NYSE:ADT) RBC starts coverage with an "outperform" and a price target of \$12 (U.S.), giving the stock 51% upside.

Aramark (NYSE:ARMK) RBC begins coverage with an "outperform" and a target of \$47, implying 29% gains.

**

LyondellBasell Industries (NYSE:LYB) RBC upgrades to "outperform" and boosts the target to \$130 from \$114, giving the stock 44% upside potential.

Micron Technology (NYSE:MU) Baird downgrades to "underperform"

from outperform and cuts the target to a Street low of \$32 from \$75 on weak semiconductor pricing.

STOCKS THAT MAY MOVE

MedMen (CSE:MMEN) says its CFO has quit and that it's cutting the amount of a share sale by about 40% to \$75 million.

AltaGas (TSX:ALA) names Randall Crawford as CEO.

Boston Scientific (NYSE:BSX) is buying BTG of the U.K. for \$4.2 billion.

Lowe's (NYSE:LOW) continues its restructuring saying it will sell its Mexican operations and certain non-core assets in the U.S. after announcing some store closures in Canada.

L Brands (NYSE:LB) is cutting its dividend, replacing the CEO of its Victoria's Secret brand and considering options for its unprofitable La Senza brand.

With files from The Globe and Mail, Reuters and Bloomberg News.

MARKETS

Stock futures are sharply lower and European stock indices are down on the usual suspects – concerns about slowing growth, trade tensions

and continued pressure in the tech sector.

CURRENCIES

The Canadian dollar is down 0.3% to \$0.7568 (U.S).

Bitcoin is lower by another 13% at \$4,463 as its collapse continues.

COMMODITIES

West Texas Intermediate is down 1.8% to \$56.16 a barrel.

Gold is up slightly at \$1,227.40 an ounce.

Daily Update

We've posted a couple of [new podcasts](#). They're the audio versions of our interviews with the CEOs of EastWest Bioscience and Organic Garage.

Access, insight and ideas.

Have a great weekend!

Mark Bunting

Publisher,

Capital Ideas Media



The information and recommendations made available here (“Information”) by CIR and/or all affiliates is for informational purposes only and not to be used or construed as an offer to sell or a solicitation of an offer to buy any services or securities. You further agree that neither Capital Ideas Research will be liable for any losses or liabilities that may be occasioned as a result of the information or commentary provided in the letter. By accessing the site and reading this note, you accept and agree to be bound by and comply with the terms and conditions set out herein. If you do not accept and agree to the terms, you should not use this site or accept this email.

CIR is not registered as an adviser under the securities legislation of any jurisdiction of Canada and provides the Information pursuant to an exemption from the registration requirements that is available in respect of generic advice. The recommendations contained on the site and in this email are not tailored to the needs of particular persons and may not be appropriate for you depending on your financial position or investment goals or needs. You should apply your own judgment in making any use of the Information, especially as the basis for any investment decision. Prior to making any investment decision, we recommend that you seek outside advice from a qualified and registered investment advisor.

In no event will CIR be responsible or liable to you or any other party for any damages of any kind arising out of or relating to the use of, misuse of or inability to use this site and email. The Information is directed only at persons resident in Canada. Nothing in this site shall constitute an offer or solicitation to anyone in the United States of America or any jurisdiction where such offer or solicitation is not authorized or to any person to whom it is unlawful to make such a solicitation. If you choose to access this site or email from

outside of Canada, you acknowledge that the Information is intended for use by persons resident in Canada only.

This is not an investment advisory, and should not be used to make investment decisions. Information in CIR is often opinionated and should be considered for information purposes only. No stock exchange anywhere has approved or disapproved of the information contained herein. There is no express or implied solicitation to buy or sell securities. The writers and editors of CIR may have positions in the stocks discussed above and may trade in the stocks mentioned. Don't consider buying or selling any stock without conducting your own due diligence.

Copyright © 2016 Capital Ideas Research, All rights reserved.

You are receiving this email because you are part of our investment network.

[Add us to your address book](#)

[unsubscribe from this list](#) [update subscription preferences](#)

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)

Capital Ideas Research · HSBC Bank Place · 10250 101 Street Suite 1803 · Edmonton, Alberta T5J 3P4 · Canada